Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gaviscon Double Action Tablets acid neutralisation crossover study in healthy volunteers
NL-OMON42922Phase 3Withdrawn
- Sponsor
- Reckitt
- Start
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Gaviscon Double Action in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Reckitt. Primary endpoint: Mean percentage of time with pH 4 or higher over 0 to 30 minutes post-dose across electrodes 5 to 10. Planned start May 2016; status: withdrawn.
02
Drugs
Gaviscon Double Action
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NL-OMON42922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42922.